gms | German Medical Science

58. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

26. bis 29.04.2007, Leipzig

Phase I/II study of intra-operative photodynamic therapy with 5-ALA in recurrent malignant gliomas

Phase-I/II-Studie zur intraoperativen photodynamischen Therapie maligner Gliome mit 5-ALA

Meeting Abstract

  • corresponding author W. Stummer - Neurochirurgische Klinik, Universitätsklinikum Düsseldorf
  • T. Meinel - clinstud GmbH Hamburg
  • T. Beck - Laserforschungslabor, Ludwig-Maximilians-Universität, München
  • M. Sabel - Neurochirurgische Klinik, Universitätsklinikum Düsseldorf
  • J. C. Tonn - Neurochirurgische Klinik, Ludwig-Maximilians-Universität, München
  • C. Goetz - Neurochirurgische Klinik, Ludwig-Maximilians-Universität, München
  • R. Baumgartner - Laserforschungslabor, Ludwig-Maximilians-Universität, München

Deutsche Gesellschaft für Neurochirurgie. 58. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC). Leipzig, 26.-29.04.2007. Düsseldorf: German Medical Science GMS Publishing House; 2007. DocFR.04.05

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 11. April 2007

© 2007 Stummer et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Objective: ALA has been explored as an intraoperative fluorescence-marker for malignant glioma surgery and has been under experimental investigation as photosensitizer. The present prospective study was designed to elucidate safety and efficacy of ALA for intraoperative photodynamic therapy of residual tumor in patients with recurrent malignant gliomas.

Methods: 21 patients (median age 46.8 years, median KPS 100), suffering recurrent malignant glioma (WHO Grad III: n=7, WHO Grade IV n=14) with tumors amenable to surgery were included. Patients were chosen if it appeared likely that residual tumor would be left unresected in eloquent brain areas. Patients were subdivided into three successive groups for treatment with escalating light doses (100, 150, 200 J/cm2 ) after fluorescence-guided surgery using 5-ALA. Laser light (635 nm, Ceramoptec Diode Laser) was applied via a fiber/microlens system. Doses were regulated by varying the duration of irradiation (500, 750, 1000 s) using constant light intensities (200 mW). Patients were monitored for adverse events, NIH stroke score, KPS, EORTC Quality of Life Score, progression-free survival, based on MR data, and overall survival.

Results: Severe adverse events (e.g. pulmonary embolism, seizures, secondary neurological deterioration) were observed in 7 patients during the observation period, but in only one patient within 7 days after surgery. No severe adverse events were considered causally related to treatment. Progression-free survival to date was 8.2 and 13.2 months using 100 and 150 J/cm2, respectively. Median progression-free survival was not yet been reached in the 200 J/cm2 group. Overall survival was 13.8 and 15.3 months (100 and 150 J/cm2; 200 J/cm2: median survival not yet reached). Function scores revealed no dose-dependent variations.

Conclusions: Intraoperative PDT of residual tumor using 5-ALA in recurrent malignant glioma was not associated with obvious mortality related to the procedure. Promising outcomes in terms of progression-free survival and overall survival suggest that this concept should be further persued.